Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.

NCT01460472 is registered in ClinicalTrials.gov with Recombio SL as lead sponsor.

NCT NCT01460472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01460472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.
Lead sponsor
Recombio SL
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2010
Completion date
September 30, 2016
Enrollment
1,082 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell, nsclc